DRIO
Price
$0.70
Change
+$0.01 (+1.45%)
Updated
May 8 closing price
Capitalization
40.57M
5 days until earnings call
PACB
Price
$1.20
Change
+$0.07 (+6.19%)
Updated
May 8 closing price
Capitalization
976.68M
82 days until earnings call
Ad is loading...

DRIO vs PACB

Header iconDRIO vs PACB Comparison
Open Charts DRIO vs PACBBanner chart's image
DarioHealth
Price$0.70
Change+$0.01 (+1.45%)
Volume$100.02K
Capitalization40.57M
Pacific Biosciences of California
Price$1.20
Change+$0.07 (+6.19%)
Volume$10.36M
Capitalization976.68M
DRIO vs PACB Comparison Chart
Loading...
DRIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DRIO vs. PACB commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRIO is a Hold and PACB is a Buy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (PACB: $1.20)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PACB’s FA Score shows that 0 FA rating(s) are green while.

  • PACB’s FA Score: 0 green, 5 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRIO’s TA Score shows that 4 TA indicator(s) are bullish while PACB’s TA Score has 4 bullish TA indicator(s).

  • DRIO’s TA Score: 4 bullish, 6 bearish.
  • PACB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PACB is a better buy in the short-term than DRIO.

Price Growth

PACB (@Medical Specialties) experienced а +8.11% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.37%. For the same industry, the average monthly price growth was +9.27%, and the average quarterly price growth was -3.44%.

Reported Earning Dates

PACB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Medical Specialties (+0.37% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PACB($977M) has a higher market cap than DRIO($40.6M). DRIO YTD gains are higher at: -10.953 vs. PACB (-34.426). DRIO has higher annual earnings (EBITDA): -49.57M vs. PACB (-277.28M). PACB has more cash in the bank: 631M vs. DRIO (43.9M). DRIO has less debt than PACB: DRIO (29.9M) vs PACB (934M). PACB has higher revenues than DRIO: PACB (201M) vs DRIO (23.5M).
DRIOPACBDRIO / PACB
Capitalization40.6M977M4%
EBITDA-49.57M-277.28M18%
Gain YTD-10.953-34.42632%
P/E RatioN/AN/A-
Revenue23.5M201M12%
Total Cash43.9M631M7%
Total Debt29.9M934M3%
FUNDAMENTALS RATINGS
DRIO vs PACB: Fundamental Ratings
DRIO
PACB
OUTLOOK RATING
1..100
6910
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
5590
P/E GROWTH RATING
1..100
10073
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DRIO's Valuation (27) in the Medical Specialties industry is significantly better than the same rating for PACB (100) in the Biotechnology industry. This means that DRIO’s stock grew significantly faster than PACB’s over the last 12 months.

DRIO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as PACB (100) in the Biotechnology industry. This means that DRIO’s stock grew similarly to PACB’s over the last 12 months.

DRIO's SMR Rating (94) in the Medical Specialties industry is in the same range as PACB (94) in the Biotechnology industry. This means that DRIO’s stock grew similarly to PACB’s over the last 12 months.

DRIO's Price Growth Rating (55) in the Medical Specialties industry is somewhat better than the same rating for PACB (90) in the Biotechnology industry. This means that DRIO’s stock grew somewhat faster than PACB’s over the last 12 months.

PACB's P/E Growth Rating (73) in the Biotechnology industry is in the same range as DRIO (100) in the Medical Specialties industry. This means that PACB’s stock grew similarly to DRIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DRIOPACB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
Bullish Trend 1 day ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
DRIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIVIX20.80N/A
N/A
Causeway International Value Instl
HEIIX12.90N/A
N/A
Hennessy Equity and Income Institutional
BCSVX25.08N/A
N/A
Brown Capital Mgmt Intl Sm Co Inv
MSOCX27.17N/A
N/A
Morgan Stanley Inst International Opp C
ANDNX16.55-0.14
-0.84%
AQR International Defensive Style N

DRIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRIO has been loosely correlated with TWST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if DRIO jumps, then TWST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRIO
1D Price
Change %
DRIO100%
+1.21%
TWST - DRIO
34%
Loosely correlated
-0.52%
VCYT - DRIO
28%
Poorly correlated
+1.20%
XWEL - DRIO
28%
Poorly correlated
+4.83%
BNGO - DRIO
28%
Poorly correlated
+4.34%
ILMN - DRIO
27%
Poorly correlated
+4.23%
More